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 Ongoing initiatives will allow for further 
assessment of this and other public-health 
initiatives to improve the care and out-
comes of people with CKD. 2 A complete 
assessment of eGFR reporting requires a 
broader perspective on CKD than its 
impact on nephrology referral. CKD is no 
longer just about kidney failure, nor is it 
just about us, nephrologists, but includes all 
health-care professionals and the public. 
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 End-stage renal disease (ESRD) is associ-
ated with increased cardiovascular mor-
bidity and mortality, and cardiac disease is 
the leading cause of death among patients 
receiving dialysis (42 % of all-cause mortal-
ity). 1,2 In this context, the steady increase 
in the incidence of ESRD, disproportionate 
to the prevalence of chronic kidney dis-
ease, further feeds the burden of cardio-
vascular complications. Despite the wealth 
of evidence regarding atherosclerotic and 
valvular heart disease in ESRD patients, 
data on cardiac arrhythmias are limited. 2,3 
Notably, atrial  brillation (AF) has recently 
emerged as a prevalent cardiac arrhythmia 
independently associated with ESRD. 3 AF 
in the general population represents a fre-
quent arrhythmia responsible for consid-
erable morbidity and mortality because it 
independently increases the risk of death 
up to 1.9-fold and that of stroke  vefold. 
Its prevalence doubles with each decade of 
age, reaching the level of 9 % at the eighth 
decade of life. Interestingly, recent data 
point to the markedly higher prevalence of 
AF in dialysis patients compared with the 
age-matched general population. 3 – 5 
 ; e prevalence of AF in ESRD patients 
varies considerably among the reported 
studies. 3 Nevertheless, the most recent data 
derived from observational studies indicate 
a prevalence of 13 – 27 % in ESRD patients 
with a mean age between 60 and 67 years. 3,5 
Along the same lines , a recent population-
based cohort study showed a strong and 
graded inverse association between glomer-
ular  ltration rate and the prevalence of AF, 
independent of other vascular risk factors. 6 
 With respect to the incidence of AF in 
ESRD patients, only data on chronic dialy-
sis patients have been published. ; ese data 
indicate an incidence between 1 and 4.1 per 
100 patient-years. 3,5 ; e marked di4 er-
ences between the prevalence and incidence 
rates across the studies can be attributed to 
several factors, such as di4 erent ages of the 
studied populations, and di4 erences in the 
type and documentation of the recorded 
AF episodes, as well as in the time on dialy-
sis and the associated risk factors. 3 
 Vazquez  et al. 7 (this issue) extend previ-
ous observations and report on the preva-
lence and incidence of AF in a cohort of 
patients who started dialysis in their center 
and were followed for a mean period of 2 
years. ; ey also examined the total mortal-
ity and stroke incidence during this time 
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 End -stage renal disease is associated with considerable cardiovascular 
morbidity and mortality. Atrial fibrillation (AF) is prevalent among 
dialysis patients and adversely affects the clinical outcome. Vazquez  et al. 
report an increased prevalence and incidence of AF in patients who 
commence dialysis, and an independent association between arrhythmia 
and mortality risk.  Moreover, they examined clinical and laboratory 
parameters associated with AF. This population study may fuel research 
aiming at the development of novel preventive and treatment strategies. 
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period. ; is well-designed observational 
study investigated for the first time the 
prevalence and incidence of AF in chronic 
kidney disease patients who commence 
dialysis. Apparently, the prevalence of 12.1 % 
is one of the lowest reported in the litera-
ture 3 but is consistent with the fact that the 
patients were not on chronic dialysis before 
the initial assessment. On the other hand, 
the incidence of 5.9 per 100 patient-years is 
somewhat greater compared with previous 
data 3 but in keeping with the age of the 
patients and the regular and strict follow-
up, which allowed more accurate and reli-
able documentation of the arrhythmia. 7 
 More interestingly, the authors studied 
the factors associated with AF in this pop-
ulation. In previous studies, several factors 
have shown an independent association 
with AF in ESRD. 3 ; ese include increas-
ing age, coronary artery disease, le/  atrial 
dilatation, right atrial dilatation, duration 
of dialysis therapy, low performance status 
as assessed by the Karnofsky index, predi-
alysis systolic blood pressure, and type of 
dialysis (hemodialysis over peritoneal 
dialysis). 3 Vazquez  et al. 7 mention three 
risk factors that were independently asso-
ciated with AF at the start of dialysis, 
namely female gender, increased le/  atrial 
diameter, and age. On the other hand, fac-
tors associated with AF development dur-
ing the follow-up included valvular 
calci cations, pre-existent bundle branch 
block, previous stroke, lower le/  ventricular 
ejection fraction, increased pulse pressure, 
and decreased hemoglobin levels. Most of 
these associations have already been 
described in previous studies conducted in 
the general population or in ESRD patients. 
; e presence of valvular calci cations and 
the presence of anemia may represent 
indexes of severity of ESRD-associated car-
diovascular abnormalities. For example, 
anemia is a strong predictor of mortality 
and cardiovascular events in both CKD 
and heart failure. ; e predictive value of 
bundle branch block merits special atten-
tion. ; e intraventricular conduction dis-
turbances often provide a substrate for 
ventricular dyssynchrony leading to struc-
tural and electrophysiological changes that 
facilitate AF. In future studies it would be 
interesting to investigate the speci c value 
of each type of bundle branch block as well 
as the impact of QRS duration. 
 ; e study by Vazquez  et al. 7 not only rein-
forces the recently described association 
between ESRD and AF but further supports 
the unfavorable e4 ect of AF on the survival 
of these patients. 3,5,7 It should be borne in 
mind that there is a debate as to whether AF 
is an independent risk factor or simply a car-
diovascular risk marker. Remarkably, Gen-
ovesi  et al. have demonstrated that AF is 
independently associated with greater mor-
tality in a cohort of long-term hemodialysis 
patients. 5 However, AF was significantly 
associated with cardiovascular mortality but 
not non- cardiovascular death, and it was not 
related to incident stroke events. 5 Moreover, 
 Wiesholzer  et al. showed that the presence 
of AF in hemodialysis patients is not associ-
ated with increased stroke risk, and, surpris-
ingly, they found a higher rate of stroke in 
patients who were on anticoagulation or 
aspirin. 8 In the study by Vazquez  et al. , 7 no 
data on  speci c-cause mortality are reported, 
but the authors indicate that the presence of 
AF implied an almost 10-fold increase in 
ischemic stroke events. 
 Despite the aforementioned inconsist-
ent results, it seems that the thromboem-
bolic risk in ESRD patients with AF is 
elevated. 3,4 It has also been demonstrated 
that the use of warfarin is associated with 
a lower risk of mortality in ESRD patients 
a/ er hospitalization for AF. 9 Along the 
same lines, it was recently demonstrated 
that proteinuria and reduced estimated 
glomerular  ltration rate are associated 
with a higher rate of thromboembolism in 
patients with nonvalvular AF independ-
ent of other stroke risk factors. 10 
 As with any good study, the questions are 
more important than the answers. First, the 
speci c cause of mortality was not reported. 
As was mentioned before, the presence of 
AF may be related more strongly  to cardio-
vascular mortality. It should be recognized 
that in dialysis patients, sudden cardiac 
death and heart failure are the prevailing 
modes of cardiovascular death. 2 Very 
recently it was demonstrated that sudden 
death in chronic dialysis patients is highly 
and independently associated with the pres-
ence of AF. 11 Second, although AF showed 
an independent association with mortality 
in multivariate analysis, one cannot exclude 
the possibility that this simply represents a 
marker of cardiovascular pathological 
changes that accompany ESRD, as the study 
is observational and therefore cause – e4 ect 
 relationships cannot be examined. Also, 
there are no data on the drug treatment of 
the patients. Speci cally, it would be inter-
esting to examine whether there are di4 er-
ences between AF and no-AF patients 
regarding agents that potentially a4 ect car-
diac remodeling, such as angiotensin sys-
tem inhibitors, statins, and   -blockers. In 
fact, Genovesi  et al. have shown that the use 
of angiotensin-converting enzyme inhibi-
tors in hemodialysis patients was related to 
a lower incidence of new diagnoses of AF. 5 
Another methodological problem, com-
mon in many AF studies, is that the exact 
burden of the arrhythmia cannot be 
 Figure 1  |  A simplified depiction of the complex pathophysiology of atrial fibrillation in 
end-stage renal disease. ANS, autonomic nervous system; ESRD, end-stage renal disease; 
RAA, renin – angiotensin – aldosterone. 
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 accurately assessed and is actually under-
estimated. Inevitably, regular follow-up 
visits, emergency assessment of sympto-
matic patients, periodic 12-lead electrocar-
diographic recordings, and 24-h Holter 
recordings have a low yield of AF detection 
given that many episodes are brief and 
asymptomatic. ; e exact AF burden over 
long time periods can be reliably assessed 
only in patients with implanted modern 
pacemakers and implantable cardioverter 
de brilators  able to record atrial high-rate 
episodes. Another issue that needs further 
clari cation in future studies is the relative 
signi cance of di4 erent types of AF. In the 
general population it is now well established 
that paroxysmal AF carries the same risk in 
terms of morbidity and mortality compared 
with persistent and permanent AF. Whether 
there is a similar risk in the setting of ESRD 
is uncertain. ; e di4 erences in the underly-
ing etiology and pathophysiology may 
imply di4 erent e4 ects on morbidity and 
mortality. For instance, the acute changes 
in electrolyte levels and especially the rela-
tive hypokalemia have been associated with 
brief paroxysmal AF episodes. 3 
 ; e pathophysiology of AF in ESRD is 
complex ( Figure 1 ). It should be recognized 
that ESRD  per se is associated with volume 
overload and neurohormonal alterations 
(mainly activation of the sympathetic system 
and the renin – angiotensin – aldosterone sys-
tem) that promote ventricular hypertrophy 
and dilation as well as increased le/  atrial 
size and pressure. 3 Inevitably, these abnor-
malities contribute to the structural and 
electrical remodeling of the atria. In addi-
tion, inM ammation and  oxidative stress have 
been implicated in the pathophysiology of 
ESRD and represent major mechanisms of 
cardiovascular dysfunction in this setting. 
Recently, AF has been associated with 
inM ammation and oxidative stress, and much 
of the current interest regarding pharma-
cologic therapy has shi/ ed to non-channel-
blocking drugs with pleiotropic properties. 
Whether these interventions have a speci c 
value in ESRD patients is unknown. 
 In conclusion, AF is prevalent among 
ESRD patients, representing an additional 
threat in this frail population. Undoubt-
edly, further larger studies with longer 
 follow-up are needed in order to elucidate 
the impact of AF on various clinical 
parameters, as well as the role of di4 erent 
 prognostic factors and therapeutic modal-
ities in this setting. Finally, the  clari cation 
of the complex underlying pathophysiol-
ogy may favor the development of e4 ective 
preventive and  treatment strategies. 
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 Hospitalizations are frequent among dialysis patients, and reducing repeat 
hospitalizations could decrease costs and improve outcomes. Chan  et al. 
found that hemoglobin monitoring along with erythropoietin-stimulating 
agent dose modification and vitamin D administration reduced the risk of 
repeat hospitalization. These and other interventions, especially those 
related to close monitoring immediately after hospitalization and better 
communication between hospital and dialysis providers to assure continuity 
of care, should be further explored in observational or randomized studies. 
 Kidney International (2009)  76, 249 – 251.  doi: 10.1038/ki.2009.145 
see original article on page 331
of long-term hemodialysis patients .  Am J Kidney 
Dis  2008 ;  51 :  255 – 262 . 
 6 .  Iguchi  Y ,  Kimura  K ,  Kobayashi  K  et al.  Relation of 
atrial fibrillation to glomerular filtration rate .  
 Am J Cardiol  2008 ;  102 :  1056 – 1059 . 
 7 .  Vazquez  E ,  Sanchez-Perales  C ,  Garcia-Garcia  F  
 et al.  Atrial fibrillation in incident dialysis patients . 
 Kidney Int  2009 ;  76 :  324–330 . 
 8 .  Wiesholzer  M ,  Harm  F ,  Tomasec  G  et al.  Incidence 
of stroke among chronic hemodialysis patients 
with nonrheumatic atrial fibrillation .  Am J Nephrol 
 2001 ;  21 :  35 – 39 . 
 9 .  Abbott  KC ,  Trespalacios  FC ,  Taylor  AJ  et al.  Atrial 
fibrillation in chronic dialysis patients in the 
United States: risk factors for hospitalization and 
mortality .  BMC Nephrol [online]  2003 ;  4 :  1 . 
 10 .  Go  AS ,  Fang  MC ,  Udaltsova  N  et al.  Impact of 
proteinuria and glomerular filtration rate on risk 
of thromboembolism in atrial fibrillation: the 
anticoagulation and risk factors in atrial fibrillation 
(ATRIA) study .  Circulation  2009 ;  119 :  1363 – 1369 . 
 11 .  Genovesi  S ,  Valsecchi  MG ,  Rossi  E  et al.  Sudden 
death and associated factors in a historical cohort 
of chronic haemodialysis patients .  Nephrol Dial 
Transplant  advance online publication, 16 March 
2009; doi:10.1093/ndt/gfp104 . 
